The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and ...

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic ...

THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of ...

The average one-year price target for Lexicon Pharmaceuticals (NasdaqCM:LXRX) has been revised to $3.43 / share. This is an increase of 15.07% from the prior estimate of $2.98 dated February 21, 2026.

Joining me today are Dr. Michael S. Exton, Lexicon Pharmaceuticals, Inc.'s Chief Executive Officer and Director; Dr. Craig B.

THE WOODLANDS, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the completion of the sale of Lexicon’s rights, title and interest in XERMELO ® ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Lexicon Pharmaceuticals announced that it will present data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in ...

Ever since its first FDA rejection five years ago, Lexicon Pharmaceuticals hasn’t given up hope on its Type 1 diabetes prospect sotagliflozin. Now, the company’s approval dreams could be coming into ...

Investing in biotech stocks is a risky endeavor, but sometimes you can eke out a return without facing as much potential trouble as usual. By identifying companies that are likely to report rapid ...